Notice on Convening the 2025 Annual General Meeting
Filed with SSE · · 10 pages · Chinese
Shanghai Pharmaceuticals Holding Co. Ltd. on 6ix
Earlier from Shanghai Pharmaceuticals
- Announcement on Subsidiary Becoming the Marketing Authorization Holder of Trazodone Hydrochloride Tablets
- Announcement on the Interim Dividend Distribution Arrangement in 2026
- Announcement on Obtainment of Drug Registration Certificate for Rivaroxaban Tablets in Thailand
- Report for Q1 2026
- Announcement on Progress in Proposed Public Listing and Transfer of 30% Equity in Sino-American Shanghai Squibb Pharmaceuticals Co., Ltd.
Later from Shanghai Pharmaceuticals
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
- Announcement on Election of Employee Representative Director for the 9th Board of Directors
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Obtaining Approval for Production of Vigabatrin Powder for Oral Solution
- Announcement on the Completion of Implementation of Controlling Shareholder's Share Increase Plan and Results
Follow Shanghai Pharmaceuticals into a list and get an email when it puts out news.
Follow Shanghai Pharmaceuticals